Evaluation of the long-Term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France

Abstract

Objectives:The present study aimed to compare the projected long-Term clinical and cost implications associated with liraglutide, sitagliptin and glimepiride in patients with type 2 diabetes mellitus failing to achieve glycemic control on metformin monotherapy in France.Methods:Clinical input data for the modeling analysis were taken from two randomized, controlled trials (LIRA-DPP4 and LEAD-2). Long-Term (patient lifetime) projections of clinical outcomes and direct costs (2013 Euros; ) were made using a validated computer simulation model of type 2 diabetes. Costs were taken from published France-specific sources. Future costs and clinical benefits were discounted at 3% annually. Sensitivity analyses were performed.Results:Liraglutide was associated with an increase in quality-Adjusted life expectancy of 0.25 quality-Adjusted life years (QALYs) and an increase in mean direct healthcare costs of 2558 per patient compared with sitagliptin. In the comparison with glimepiride, liraglutide was associated with an increase in quality-Adjusted life expectancy of 0.23 QALYs and an increase in direct costs of 4695. Based on these estimates, liraglutide was associated with an incremental cost-effectiveness ratio (ICER) of 10,275 per QALY gained vs sitagliptin and 20,709 per QALY gained vs glimepiride in France.Conclusion:Calculated ICERs for both comparisons fell below the commonly quoted willingness-To-pay threshold of 30,000 per QALY gained. Therefore, liraglutide is likely to be cost-effective vs sitagliptin and glimepiride from a healthcare payer perspective in France.